Figure 3.
Axi-cel response rates by V2Vt. Response rate (A), adjusted ORs of ORR and CR (B), and adjusted DOR (C) by V2Vt in patients treated with axi-cel. Patients were from the CIBMTR registry PASS Cohort. Covariates for stepwise selection and multivariable adjustment were age, sex, race, ethnicity, ECOG PS before infusion, comorbidities (pulmonary, cardiac/cerebrovascular/heart valve disease, hepatic, and renal), histologic transformation, disease characteristics at initial diagnosis (double/triple hit, disease stage, elevated LDH, and >1 extranodal involvement), chemosensitivity before infusion, number of lines of prior therapy, prior HCT, year of infusion, time from initial diagnosis to infusion, and use of bridging therapy. PR, partial response.

Axi-cel response rates by V2Vt. Response rate (A), adjusted ORs of ORR and CR (B), and adjusted DOR (C) by V2Vt in patients treated with axi-cel. Patients were from the CIBMTR registry PASS Cohort. Covariates for stepwise selection and multivariable adjustment were age, sex, race, ethnicity, ECOG PS before infusion, comorbidities (pulmonary, cardiac/cerebrovascular/heart valve disease, hepatic, and renal), histologic transformation, disease characteristics at initial diagnosis (double/triple hit, disease stage, elevated LDH, and >1 extranodal involvement), chemosensitivity before infusion, number of lines of prior therapy, prior HCT, year of infusion, time from initial diagnosis to infusion, and use of bridging therapy. PR, partial response.

This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal